TEST BANK For Pharmacotherapeutics for Advanced Practice Nurse Prescribers, 6th Edition by Woo & Wright, All 57 Chapters Covered, Verified Latest Edition

lOMoAR cPSD| 21007614




lOMoAR cPSD| 2100




TEST BANK For Pharmacotherapeutics for Advanced Practice
Nurse Prescribers, 6th Edition by Woo & Wright, All 57
Chapters Covered, Verified Latest Edition


Chapter 1 Issues for the Practitioner in Drug Therapy
i i i i i i i i




MULTIPLE CHOICE i




1. Nurse practitioner prescriptive authority is regulated by:
i i i i i i




A. The National Council of State Boards of Nursing
i i i i i i i




B. The U.S. Drug Enforcement Administration
i i i i




C. The State Board of Nursing for each state
i i i i i i i




D. The State Board of Pharmacy i i i i




ANS: i C PTS: i 1

2. Physician Assistant (PA) prescriptive authority is regulated by:
i i i i i i i




A. The National Council of State Boards of Nursing
i i i i i i i




B. The U.S. Drug Enforcement Administration
i i i i




C. The State Board of Nursing i i i i




D. The State Board of Medical Examiners
i i i i i




ANS: i D PTS: i 1

3. Clinical judgment in prescribing includes:
i i i i




A. Factoring in the cost to the patient of the medication prescribed i i i i i i i i i i




B. Always prescribing the newest medication available for the disease process
i i i i i i i i i




C. Handing out drug samples to poor patients i i i i i i




D. Prescribing all generic medications to cut costs i i i i i i




ANS: i A PTS: i 1

4. Criteria for choosing an effective drug for a disorder include:
i i i i i i i i i




A. Asking the patient what drug they think would work best for them
i i i i i i i i i i i




B. Consulting nationally recognized guidelines for disease management i i i i i i




C. Prescribing medications that are available as samples before writing a prescription i i i i i i i i i i




D. Following U.S. Drug Enforcement Administration (DEA) guidelines i i i i i i




i forprescribing
i




ANS: i B PTS: i 1

5. Nurse practitioner practice may thrive under health-care reform due to:
i i i i i i i i i




A. The demonstrated ability of nurse practitioners to control costs and improve
i i i i i i i i i i




patientoutcomes
i i




B. The fact that nurse practitioners will be able to practice independently
i i i i i i i i i i




C. The fact that nurse practitioners will have full reimbursement under health-
i i i i i i i i i i




carereform i




D. The ability to shift accountability for Medicaid to the state level
i i i i i i i i i i




Downloaded by Patrick Liquete () i i i i

, lOMoAR cPSD| 21007614




ANS: i A PTS: i 1




Chapter 2.Pharmacokinetic Basis of Therapeutics and Pharmacodynamic
i i i i i i




MULTIPLE CHOICE i




1. A patient's nutritional intake and lab work reflects hypoalbuminemia. This is critical
i i i i i i i i i i i




toprescribing because:
i i i




A. Distribution of drugs to target tissue may be affected i i i i i i i i




B. The solubility of the drug will not match the site of absorption
i i i i i i i i i i i




C. There will be less free drug available to generate an effect
i i i i i i i i i i




D. Drugs bound to albumin are readily excreted by the kidney
i i i i i i i i i




ANS: i A PTS: i 1

2. Drugs that have a significant first-pass effect:
i i i i i i




A. Must be given by the enteral (oral) route only
i i i i i i i i




B. Bypass the hepatic circulation i i i




C. Are rapidly metabolized by the liver and may have little if any desired action
i i i i i i i i i i i i i




D. Are converted by the liver to more active and fat-soluble forms
i i i i i i i i i i




ANS: i C PTS: i 1

3. The route of excretion of a volatile drug will likely be:
i i i i i i i i i i




A. The kidneys i




B. The lungs i




C. The bile and feces i i i




D. The skin i




ANS: i B PTS: i 1

4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of i i i i i i i i i i i




i thedrug. Storage reservoirs:
i i i




A. Assure that the drug will reach its intended target tissue i i i i i i i i i




B. Are the reason for giving loading doses
i i i i i i




C. Increase the length of time a drug is available and active i i i i i i i i i i




D. Are most common in collagen tissues
i i i i i




ANS: i C PTS: i 1

5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug's:
i i i i i i i i i i i i i i




A. Propensity to go to the target receptor i i i i i i




B. Biological half-life i




C. Pharmacodynamics
D. Safety and side effects i i i




ANS: i B PTS: i 1

Downloaded by Patrick Liquete () i i i i

, lOMoAR cPSD| 21007614




6. Azithromycin dosing requires the first day's dose be twice those of the other 4 days of
i i i i i i i i i i i i i i i




theprescription. This is considered a loading dose. A loading dose:
i i i i i i i i i i i




A. Rapidly achieves drug levels in the therapeutic range
i i i i i i i




B. Requires four to five half-lives to attain
i i i i i i




C. Is influenced by renal function
i i i i




Downloaded by Patrick Liquete ()
i i i i

, lOMoAR cPSD| 21007614




D. Is directly related to the drug circulating to the target tissues
i i i i i i i i i i




ANS: i A PTS: 1 i i i




7. The point in time on the drug concentration curve that indicates the first sign of a
i i i i i i i i i i i i i i i




therapeuticeffect is the:
i i i i




A. Minimum adverse effect level i i i




B. Peak of action i i




C. Onset of action i i




D. Therapeutic range i




ANS: i C PTS: i 1

8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
i i i i i i i i i i i i




A. When the drug has a wide therapeutic range i i i i i i i




B. When the drug will be administered for a short time only
i i i i i i i i i i




C. When there is a high correlation between the dose and saturation of receptor sites
i i i i i i i i i i i i i




D. To determine if a drug is in the therapeutic range
i i i i i i i i i




ANS: i D PTS: i 1

9. A laboratory result indicates the peak level for a drug is above the minimum
i i i i i i i i i i i i i




toxicconcentration. This means that the:
i i i i i i




A. Concentration will produce therapeutic effects i i i i




B. Concentration will produce an adverse response i i i i i




C. Time between doses must be shortened i i i i i




D. Duration of action of the drug is too long i i i i i i i i




ANS: i B PTS: i 1

10. Drugs that are receptor agonists may demonstrate what property?
i i i i i i i i




A. Irreversible binding to the drug receptor site i i i i i i




B. Up-regulation with chronic use i i i




C. Desensitization or down-regulation with continuous use i i i i i




D. Inverse relationship between drug concentration and drug action i i i i i i i




ANS: i C PTS: i 1

11. Drugs that are receptor antagonists, such as beta blockers, may cause:
i i i i i i i i i i




A. Down-regulation of the drug receptor i i i i




B. An exaggerated response if abruptly discontinued
i i i i i




C. Partial blockade of the effects of agonist drugs i i i i i i i




D. An exaggerated response to competitive drug agonists
i i i i i i




ANS: i B PTS: i 1

12. Factors that affect gastric drug absorption include:
i i i i i i




A. Liver enzyme activity i i




B. Protein-binding properties of the drug molecule i i i i i




C. Lipid solubility of the drug i i i i




D. Ability to chew and swallow i i i i




ANS: i C PTS: i 1




WWW.TEGTBANKTANK.COM
Downloaded by Patrick Liquete () i i i i